Aumolertinib shows improved progression-free survival in stage III non-small cell lung cancer
The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival compared to placebo without any significant new adverse reactions, according to data from the POLESTAR ...
7 hours ago
0
0